case_images: PMC11666682_01
case_images: Timeline of the most important clinical events. On the upper graph, trends in biochemical parameters are reported. Below, the most important clinical and laboratory findings are reported. CKRT, continuous kidney replacement therapy; IHD, intermittent hemodialysis; LDH, lactate dehydrogenase; HUS, hemolytic uremic syndrome; ADAMST13, a disintegrin and metalloproteinase with thrombospondin type 1 motif member 13; STEC, Shiga toxin-producing Escherichia coli; CFH, complement factor H; CFHR, complement factor H-related genes; Abs, antibodies
case_images: 467_2024_6480_Fig1_HTML.jpg
case_images: PMC11666682_01_467_2024_6480_Fig1_HTML.jpg
case_images: Fig1
case_images: AKI stage KDIGO 3 (creatinine: 9.86 mg/dL, urea: 355 mg/dL), microangiopathic anemia (hemoglobin: 7.4 g/dL, lactate dehydrogenase: 1585 IU/L, haptoglobin: < 2 g/dL), thrombocytopenia (platelets: 48,000/mm3), low C3 level (59 mg/dL), and cardiac involvement (NT-terminal pro B-type natriuretic peptide: 14,832 pg/mL, and septal hypokinesia) (Fig. 1). Given the severe neurological and kidney involvement, therapy with the monoclonal humanized anti-C5 antibody eculizumab was initiated, supplemented by supportive therapies such as continuous kidney replacement therapy (CKRT), plasma and blood transfusions, and intravenous antihypertensive drugs.